TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07006025: A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

Sponsor: Treebough Therapies · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,454,128

Rescue Site Savings

+$2,280,176

Unlock Full NCT07006025 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07006025 Rescue Dossier →